default author photo

Alberto Farolfi

IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST) - Clinical and Experimental Oncology Unit

SCHOLARLY PAPERS

3

DOWNLOADS

413

TOTAL CITATIONS

0

Scholarly Papers (3)

1.

Safety and Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Penile Squamous Cell Carcinoma: An International Study from the Global Society of Rare Genitourinary Tumors

Number of pages: 21 Posted: 31 Mar 2023
Harvard University - Lank Center for Genitourinary Oncology, Yale University - Yale New Haven Hospital (YNHH), McMaster University, Emory University - School of Medicine, Emory University School of Medicine - Department of Urology, Emory University - Department of Hematology and Medical Oncology, New York University (NYU) - Grossman School of Medicine, Government of the United States of America - National Cancer Institute, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Arkansas for Medical Sciences, University of Texas at Houston - Department of Melanoma Medical Oncology, Gustave Roussy, Gustave Roussy, University of Parma, Istituto Oncologico Veneto – IRCCS, Ohio State University (OSU) - Comprehensive Cancer Center, Ohio State University (OSU) - The James Comprehensive Cancer Center, Ohio State University (OSU) - The James Comprehensive Cancer Center, Hospital Universitario 12 de Octubre, Hospital Universitario 12 de Octubre, Hospital Universitario 12 de Octubre, University of Florence - Department of Health Sciences, Careggi University Hospital of Florence - Clinical Oncology Unit, University of California, San Diego (UCSD) - Moores Cancer Center, University Campus Bio-Medico, Imperial College London - Hammersmith Hospital, University of California, University of California, Stanford University, Stanford University, Mayo Clinic - Department of Cardiovascular Medicine, Indiana University Purdue University Indianapolis (IUPUI) - Indiana University School of Medicine, Mount Sinai Health System - Division of Hematology and Medical Oncology, Mount Sinai Health System - Icahn School of Medicine, Hospital de la Santa Creu i Sant Pau - Medical Oncology Department, Università degli Studi di Bari “Aldo Moro” (UNIBA), Vanderbilt University - Vanderbilt-Ingram Cancer Center, Duke University - Duke University Hospital, Duke University - Duke University Hospital, National Cancer Centre Singapore, University of Parma, Ruhr University of Bochum - University Hospitals, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST) - Clinical and Experimental Oncology Unit, University of Ulsan - Asan Medical Center, University of North Carolina (UNC) at Chapel Hill - Lineberger Comprehensive Cancer Center, University of Pittsburgh - Division of Hematology/Oncology, University of Pittsburgh - Division of Hematology/Oncology, Yale University - Yale New Haven Children's Hospital, Harvard University - Dana-Farber Cancer Institute, Harvard University - Lank Center for Genitourinary Oncology, H. Lee Moffitt Cancer Center and Research Institute, Università Vita-Salute San Raffaele - IRCCS San Raffaele Scientific Institute, National Institutes of Health (NIH) - Bladder Cancer Section and Advent Health Cancer Institute - Division of Medical Oncology
Downloads 246 (311,323)

Abstract:

Loading...

penile cancer, immune checkpoint inhibitors, international cohort, rare disease

2.

MITO END-3: A Randomized Phase II Trial of Avelumab Plus Carboplatin and Paclitaxel Compared to Carboplatin and Paclitaxel in Advanced or Recurrent Endometrial Cancer

Number of pages: 32 Posted: 27 Dec 2022
Istituto Nazionale Tumori - IRCCS Fondazione G. Pascale - Uro-Gynecological Medical Oncology, Catholic University of the Sacred Heart, Rome - Gynecologic Oncology Unit, Istituto Nazionale Tumori - IRCCS Fondazione G. Pascale - Clinical Trial Unit, Istituto Nazionale Tumori - IRCCS Fondazione G. Pascale - Clinical Trial Unit, Istituto Nazionale Tumori - IRCCS Fondazione G. Pascale - Uro-Gynecological Medical Oncology, Centro di Riferimento Oncologico - Medical Oncology and Oncological Prevention Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST) - Clinical and Experimental Oncology Unit, Azienda Sanitaria Universitaria Friuli Centrale - Oncology Department, “Senatore Antonio Perrino” Hospita - Medical Oncology Unit, Baylor University - Lester and Sue Smith Breast Center, Oncology Unit, “S. Vincenzo” Hospital, S. Maria delle Croci Hospital - Oncology Unit, Infermi Hospital - Medical Oncology Unit, Mater Salutis Hospital AULSS9, “Scaligera” - Medical Oncology Unit, Medical Oncology Unit “Santo Stefano” Hospital, Niguarda Ca' Granda Hospital - Oncology Unit, IRCCS Ospedale Policlinico San Martino - U.O. Clinica di Oncologia Medica, Istituto Nazionale Tumori - IRCCS Fondazione G. Pascale - Uro-Gynecological Medical Oncology, Fondazione Policlinico Universitario A. Gemelli IRCCS - Department of Woman, Child and Public Health, Centro di Riferimento Oncologico - Medical Oncology and Oncological Prevention Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST) - Clinical and Experimental Oncology Unit, Istituto Nazionale Tumori - IRCCS Fondazione G. Pascale - Uro-Gynecological Medical Oncology, Catholic University of the Sacred Heart, Rome - Gynecologic Oncology Unit, Istituto Nazionale Tumori - IRCCS Fondazione G. Pascale - Clinical Trial Unit, Istituto Nazionale Tumori - IRCCS Fondazione G. Pascale - Microenvironment Molecular Targets Unit, Istituto Nazionale Tumori - IRCCS Fondazione G. Pascale - Microenvironment Molecular Targets Unit, Istituto Nazionale Tumori - IRCCS Fondazione G. Pascale - Microenvironment Molecular Targets Unit, Istituto Nazionale Tumori - IRCCS Fondazione G. Pascale - Pathological Anatomy and Cytopathology Unit, University of Campania “Luigi Vanvitelli” - Medical Statistics and Istituto Nazionale Tumori - IRCCS Fondazione G. Pascale - Clinical Trial Unit
Downloads 127 (572,948)

Abstract:

Loading...

Endometrial Cancer, First-line treatment, Chemotherapy, Avelumab

3.

Effect of HPV Vaccination after Cervical Intraepithelial Neoplasia on the Risk of Cervical Cancer: A Real-World, Propensity Score-Matched Cohort Study

Number of pages: 17 Posted: 29 Jan 2026
IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST) - Clinical and Experimental Oncology Unit, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST) - Clinical and Experimental Oncology Unit, AUSL Romagna, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST), AUSL Romagna, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST), AUSL Romagna, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST), TriNetX LLC, IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST), AUSL Romagna and IRCCS Istituto Romagnolo per lo Studio dei Tumori "Dino Amadori" (IRST) - Clinical and Experimental Oncology Unit
Downloads 40 (1,183,237)

Abstract:

Loading...

Human papillomavirus vaccine, Cervical intraepithelial neoplasia, Cervical cancer prevention, Adjuvant vaccination, Propensity score matching, Real-world evidence